Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 11;55(19):8350-63.
doi: 10.1021/jm300686p. Epub 2012 Sep 27.

14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects

Subramaniam Ananthan  1 , Surendra K Saini, Christina M Dersch, Heng Xu, Nicholas McGlinchey, Denise Giuvelis, Edward J Bilsky, Richard B Rothman
Affiliations

14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects

Subramaniam Ananthan et al. J Med Chem. .

Abstract

In the search for opioid ligands with mixed functional activity, a series of 5'-(4-chlorophenyl)-4,5α-epoxypyridomorphinans possessing alkoxy or acyloxy groups at C-14 was synthesized and evaluated. In this series, the affinity and functional activity of the ligands were found to be influenced by the nature of the substituent at C-14 as well as by the substituent at N-17. Whereas the incorporation of a 3-phenylpropoxy group at C-14 on N-methylpyridomorhinan gave a dual MOR agonist/DOR agonist 17h, its incorporation on N-cyclopropylmethylpyridomorphinan gave a MOR agonist/DOR antagonist 17d. Interestingly, 17d, in contrast to 17h, did not produce tolerance or dependence effects upon prolonged treatment in cells expressing MOR and DOR. Moreover, 17d displayed greatly diminished analgesic tolerance as compared to morphine upon repeated administration, thus supporting the hypothesis that ligands with MOR agonist/DOR antagonist functional activity could emerge as novel analgesics devoid of tolerance, dependence, and related side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of the effects of chronic drug treatment on DAMGO-mediated inhibition of forskolin-stimulated cAMP accumulation in MOR/DOR dimer cells: MOR/DOR dimer cells were treated for 20 h with morphine (1 µM), or 17d (30 nM), or 17h (30 nM), respectively. DAMGO-mediated inhibition of forskolin-stimulated cAMP accumulation was performed as described in Methods section. Data are presented as the EC50 ratio (fold over control). Each value is the mean ± SEM (n=3). *p<0.05 when compared with the control cells (two-tailed Student’s t-test).
Figure 2
Figure 2
Comparison of the effects of chronic drug treatment on spontaneous and naloxone (10 µM)-induced cAMP overshoot in MOR/DOR dimer cells: MOR/DOR dimer cells were treated for 20 h with morphine (1 µM), or 17d (30 nM), or 17h (30 nM), respectively. The forskolin-stimulated cAMP accumulation was assessed as described in Methods. Each value is the mean ± SEM (n=3). *p<0.05 when compared with no addition condition of the control cells. #p<0.05 when compared with no addition condition of the morphine-treated or 17h-treated cells (two-tailed Student’s t-test).
Figure 3
Figure 3
Antinociceptive dose– and time–response curves for 17d and 17e in the 55 °C warm-water tail-withdrawal assay.
Figure 4
Figure 4
Antinociceptive dose–response curves for naive control mice and mice injected repeatedly with A90 doses of 17d (left panel) or morphine (right panel) i.c.v. twice daily for 3 days.
Scheme 1
Scheme 1
Synthesis of 14-Alkoxypyridomorphinans 17a–ha aReagents and conditions: (a) NaH, DMF, Me2SO4 or R′Br, 0 °C to rt; (b) BBr3, CH2Cl2, −78 °C to rt.
Scheme 2
Scheme 2
Synthesis of 14-Acyloxypyridomorphinans 18a–f and 21–23a aReagents and conditions: (a) R′COCl, Et3N, DMF or PhMe; (b) K2CO3, MeOH-H2O, rt; (c) PhCOCl, Et3N, DMF.
Chart 1<sup>a</sup>
Chart 1a
aCPM = cyclopropylmethyl
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCurdy CR, Prisinzano TE. Opiod Receptor Ligands. In: Abraham DJ, Rotella DP, editors. Burger's Medicinal Chemistry, Drug Discovery and Development. 7th ed. Vol. 8. New York, NY: John Wiley & Sons; 2010. pp. 569–735.
    1. Marcus DA, Cope DK, Deodhar A, Payne R. Chronic Pain: An Atlas of Investigation and Management. Oxford: Clinical Publishing; 2009. Chronic pain management strategies; pp. 17–38.
    1. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120. - PubMed
    1. Zollner C, Stein C. Opioids. Handbook Exp Pharmacol. 2007:31–63. - PubMed
    1. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 1996;48:567–592. - PubMed

Publication types

MeSH terms

Substances